1000TiP Novel next generation PARP1-selective and CNS penetrant inhibitor DSB2455: A phase Ia/Ib open label, multi-centre dose escalation study with expansion cohorts to assess the safety, tolerability, and activity as monotherapy in participants with advanced malignancies
Saved in:
| Title: | 1000TiP Novel next generation PARP1-selective and CNS penetrant inhibitor DSB2455: A phase Ia/Ib open label, multi-centre dose escalation study with expansion cohorts to assess the safety, tolerability, and activity as monotherapy in participants with advanced malignancies |
|---|---|
| Authors: | Yarza, R.1 (AUTHOR), Garralda, E.2 (AUTHOR), Sánchez Perez, V.3 (AUTHOR), De Velasco Oria, G.A.4 (AUTHOR), Lorusso, P.M.5 (AUTHOR), Rodríguez, R.M.6 (AUTHOR), Kristeleit, R.S.7 (AUTHOR), Ring, A.8 (AUTHOR), Yap, C.9 (AUTHOR), Rekowski, J.10 (AUTHOR), Dickinson, P.11 (AUTHOR), Ruston, L.12 (AUTHOR), Mcguinness, B.13 (AUTHOR), Cowley, P.13 (AUTHOR), Campbell, G.14 (AUTHOR), Wise, A.15 (AUTHOR), Thomson, C.13 (AUTHOR), Landers, D.16 (AUTHOR), Yap, T.A.17 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS653-S653. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.1569 |
